News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Role of temozolomide (TMZ) for brain relapsed tumors: preliminary results Use of temodar as sole chemotherapy agent showed positive results in pts who had already had surgery, radiotherapy and chemotherapy and had recurrence of tumor.


Posted on: 05/26/2002

Role of temozolomide (TMZ) for brain relapsed tumors: preliminary results

Antonio Santoro, Massimiliano Santoro, Luigi Maiorino, San Gennaro Hospital, Naples, Italy.

Background: Despite of new integrated approaches (surgery + radiotherapy and chemotherapy), the prognosis for patients affected by malignant brain tumors is still inauspicious. TMZ is a novel alkylant chemotherapeutic drug which has been shown to have antitumor activity in these particular case.

Purpose: to value the efficacy and toxicity of monochemotheraputical TMZ treatment in patients with brain tumors relapsed after surgical and radiotherapeutical treatment.

Methods: 18 patients (13 afflicted by glioblastoma and 5 by anaplastic astrocytoma) with a median age of 60 years and median performance status (ECOG) of 2, have been registered to the study. All the patients enrolled were treated with TMZ according to a weekly therapeutical scheme: 150 mg/m2/die for 5 consecutive days; the cycle has been repeated every 28 days x 6.

Results: 1 patient died for an heart failure. After 6 complete cycles, 3 patients achieved a complete response while 6 presented a partial response >50%. Besides, 4 stable diseases and 4 progression of disease have been registered. An acceptable systemic toxicity has been obtained. Grade 3 (WHO) neutropenia has been observed in 11 patients; at the end of the 4th cycle, 1 patient was afflicted by a grade IV neutropenia well controlled with Granulocyte Colony Stimulating Factor (rhu G-CSF) administration.

Conclusion: these preliminary data (median follow-up of 18 months), confirm that TMZ administered as a single chemotherapeutic agent showed a good efficacy and tolerability with a moderate toxicity in patients with brain relapsed tumors.
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740